

Trace Impurity identification using Q-TOF mass spectroscopy

Authors: Dr John Malone, Dr Alan Thompson and Dr Osama Chahrour




Background:

The FDA and International Conference on Harmonization have set strict requirements regarding impurities in APIs and formulated drug products. These define thresholds at which impurities must be identified or adequately tested. Investigations are initiated during the early stages of drug discovery or product development such as the pre-investigational new drug (pre-IND) stage.

Accurate Mass Spectrometry (MS) techniques are ideally suited to aid in the structural elucidation of trace impurities. A rapid approach used for the isolation and characterisation of trace impurities in drug substances and formulated drug products has been developed. The approach has been successfully employed for the characterisation of impurities from different substances covering a wide variety of structural classes. A case study is presented herein.

Outline of the impurity isolation and structure elucidation work flow


Molecular Feature Extraction (MFE) and molecular formula generation (MFG) algorithms, along with MassHunter Molecular Structure Correlator (MSC) greatly aid impurity identification and structure elucidation using accurate mass and targeted MS/MS data.



Impurity ID by accurate mass LC-MS/MS (LC-ESI-QTOF)


Almac completed a laboratory feasibility study and manufactured a demonstration batch of API. The work involved analytical and process development to enable safe and reliable process scale-up and API stability evaluation conforming to cGMP.

Structure of API




Optimised accurate mass impurity profiling successfully identified the molecular formula of all impurity peaks present in the API chromatography with high score using MFE and MFG algorithms.

Accurate mass impurity profiling




Almac conducted a stability trial on the API to investigate a range of diluents, stabilisers and conditions. Impurity A concentration increased upon incubation and structural elucidation was necessary.

Stability study revealed increases in Impurity A




MS compatible method was developed and total ion chromatogram was collected (ESI-).

Total ion chromatogram



Blank subtraction and peak extraction of the previous chromatogram yielded the following accurate mass spectrum:

Mass spectrum of impurity A



The MFG algorithm successfully identified the formula with a high score reflecting accurate-theoretical mass matching and excellent isotopic distribution matching.


Compound Table

Compound Label	RT	Mass	Formula	MFG Formula	MFG Diff (ppm)	DB Formula
Cpd 1: C40 H66 O5	12.499	626.493	C40 H66 O5	C40 H66 O5	-3.16	C40 H66 O5

Predicted Isotope Match Table


Isotope	m/z	Calc m/z	Diff (ppm)	Abund %	Calc Abund %	Abund Sum %	Calc Abund Sum %
1	625.4857	625.4837	-3.09	100	100	63.86	63.88
2	626.4896	626.4872	-3.96	44.65	44.2	28.51	28.23
3	627.492	627.4903	-2.73	10.28	10.56	6.57	6.75
4	628.4941	628.4933	-1.15	1.65	1.79	1.06	1.14

Predicted isotope match



MS/MS fragmentation pattern @ 30 eV displayed three major daughter ions. The MFG algorithm successfully identified the daughter ions formula enabling the elucidation of the structure of the impurity.


Targeted MS/MS fragmentation



Peak List

m/z	Abund	Formula
221.1552	1	51347.2 C14 H21 O2
222.1586	1	8394
303.2339	1	87005.1 C20 H31 O2
304.2371	1	21094.2
321.2444	1	65634.5 C20 H33 O3
322.2475	1	15864.4

Elucidation of Impurity A structure



Conclusion:

The structure of the trace impurity A was successfully determined using Accurate Mass analysis by a Q-TOF mass spectrometer. The targeted MS/MS algorithm successfully identified the general chemical formulas of the impurity molecular and daughter ions. The information was used to elucidate the detailed chemical structure.

Global analytical services

Almac provide small molecule and peptide drug development services with expertise in API supply, biocatalysis technology, ^{14}C radiolabelling and physical sciences. We provide a full suite of analytical testing services across our FDA approved global laboratories including method development, validation, transfer and stability studies on small molecule, biologics, active ingredients and finished products (including controlled substances). Almac's team of >250 analysts have the capacity and capability to deliver your project.

Think Almac for analytical outsourcing services.

almacgroup.com

Get in touch

Global HQ
+44 28 3833 2200

US HQ
+1 215 660 8500

Athlone, Ireland
+353 90 646 0200

almacanalytical@almacgroup.com